Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor. P276-00 exhibited significant tumour reduction in animal models with less adverse effects.Based on the results from various in-vitro studies, P276-00 could be a potential candidate as a new mechanism based drug for the treatment of cancer.This Phase I study will determine the Maximum Tolerated Dose,Dose Limiting Toxicity and efficacy of P 276-00 in patients with advanced Refractory neoplasms.
Epistemonikos ID: 4690dff63844c34b0bd352e0a07fffd7291c9101
First added on: May 04, 2024